Analysts Set Astrana Health, Inc. (NASDAQ:ASTH) Price Target at $43.00

Shares of Astrana Health, Inc. (NASDAQ:ASTH) have earned a consensus recommendation of “Moderate Buy” from the twelve ratings firms that are covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $41.3333.

A number of equities analysts have recently weighed in on ASTH shares. Zacks Research downgraded shares of Astrana Health from a “hold” rating to a “strong sell” rating in a research note on Monday, November 10th. Barclays lowered their target price on Astrana Health from $36.00 to $26.00 and set an “equal weight” rating on the stock in a research note on Monday, November 24th. Needham & Company LLC began coverage on Astrana Health in a research note on Friday. They set a “buy” rating and a $28.00 price target for the company. TD Cowen reduced their price target on Astrana Health from $40.00 to $35.00 and set a “buy” rating for the company in a report on Monday, November 10th. Finally, BTIG Research lowered their price target on Astrana Health from $50.00 to $45.00 and set a “buy” rating for the company in a research note on Friday, November 7th.

Astrana Health Stock Performance

ASTH stock opened at $23.47 on Friday. The firm has a 50 day simple moving average of $26.99 and a 200 day simple moving average of $26.79. Astrana Health has a 52 week low of $20.12 and a 52 week high of $39.97. The stock has a market cap of $1.32 billion, a P/E ratio of 123.53, a P/E/G ratio of 1.41 and a beta of 0.87. The company has a debt-to-equity ratio of 1.27, a quick ratio of 1.40 and a current ratio of 1.40.

Astrana Health (NASDAQ:ASTH) last released its quarterly earnings data on Wednesday, January 10th. The company reported $0.50 earnings per share for the quarter. The firm had revenue of $317.00 million for the quarter. Astrana Health had a net margin of 0.33% and a return on equity of 1.26%. Research analysts anticipate that Astrana Health will post 1.15 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Jacobs Levy Equity Management Inc. raised its holdings in shares of Astrana Health by 19.2% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 500,527 shares of the company’s stock valued at $14,190,000 after purchasing an additional 80,465 shares in the last quarter. CANADA LIFE ASSURANCE Co increased its position in Astrana Health by 5.5% during the third quarter. CANADA LIFE ASSURANCE Co now owns 43,855 shares of the company’s stock worth $1,270,000 after buying an additional 2,285 shares during the last quarter. Dark Forest Capital Management LP bought a new position in Astrana Health during the third quarter valued at about $813,000. Verition Fund Management LLC raised its holdings in Astrana Health by 18.7% during the third quarter. Verition Fund Management LLC now owns 30,079 shares of the company’s stock valued at $853,000 after buying an additional 4,748 shares in the last quarter. Finally, Prelude Capital Management LLC acquired a new stake in shares of Astrana Health in the third quarter worth about $351,000. Institutional investors and hedge funds own 52.77% of the company’s stock.

About Astrana Health

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.